Development of molecularly targeted agents and immunotherapies in small cell lung cancer

European Journal of Cancer

Volumn 60, Issue , 2016, Pages 26-39

  Sharp, Adam ^a,b   Bhosle, Jaishree ^a   Abdelraouf, Fatma ^a,c   Popat, Sanjay ^a,d   O'Brien, Mary ^a   Yap, Timothy A ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CAIRO UNIVERSITY   (Egypt)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Antibody drug conjugate; Apoptosis; Cell signalling; DNA repair; Immunotherapies; Molecular analysis; Precision medicine; Small cell lung cancer; Targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DNA; DRUG ANTIBODY; IMMUNOMODULATING AGENT; IPILIMUMAB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIVOLUMAB; ROVALPITUZUMAB TESIRINE; SUNITINIB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

APOPTOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; DNA DAMAGE; DNA REPAIR; DRUG CONJUGATION; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IMMUNOMODULATION; INTRACELLULAR SIGNALING; LUNG CARCINOGENESIS; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMALL CELL LUNG CANCER; TUMOR VASCULARIZATION; CELL COMMUNICATION; CELL CYCLE CHECKPOINT; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES; SMALL CELL LUNG CARCINOMA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL COMMUNICATION; CELL CYCLE CHECKPOINTS; DNA DAMAGE; DNA REPAIR; DRUG DISCOVERY; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE; SMALL CELL LUNG CARCINOMA;

EID: 84962665267     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.03.004     Document Type: Review

References (83)

1. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J.W. Coebergh, H. Comber, and et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 6 2013 1374 1403
2. R. Govindan, N. Page, D. Morgensztern, W. Read, R. Tierney, A. Vlahiotis, and et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 28 2006 4539 4544
3. P. Bordi, M. Tiseo, F. Barbieri, M. Bavieri, G. Sartori, A. Marchetti, and et al. Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients Lung Cancer 86 3 2014 324 328
4. J.S. Ross, K. Wang, O.R. Elkadi, A. Tarasen, L. Foulke, C.E. Sheehan, and et al. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer J Clin Pathol 67 9 2014 772 776
5. K. Wakuda, H. Kenmotsu, M. Serizawa, Y. Koh, M. Isaka, S. Takahashi, and et al. Molecular profiling of small cell lung cancer in a Japanese cohort Lung Cancer 84 2 2014 139 144
6. G. Metro, S. Duranti, M.J. Fischer, F. Cappuzzo, and L. Crino Emerging drugs for small cell lung cancer-an update Expert Opin Emerg Drugs 17 1 2012 31 36
7. M. Peifer, L. Fernandez-Cuesta, M.L. Sos, J. George, D. Seidel, L.H. Kasper, and et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer Nat Genet 44 10 2012 1104 1110
8. C.M. Rudin, S. Durinck, E.W. Stawiski, J.T. Poirier, Z. Modrusan, D.S. Shames, and et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer Nat Genet 44 10 2012 1111 1116
9. S. Umemura, S. Mimaki, H. Makinoshima, S. Tada, G. Ishii, H. Ohmatsu, and et al. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis J Thorac Oncol 9 9 2014 1324 1331
10. S. Umemura, K. Tsuchihara, and K. Goto Genomic profiling of small-cell lung cancer: the era of targeted therapies Jpn J Clin Oncol 2015
11. A.M. Arnold, L. Seymour, M. Smylie, K. Ding, Y. Ung, B. Findlay, and et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20 J Clin Oncol 25 27 2007 4278 4284
12. C. Belani, S. Dahlberg, C. Rudin, M. Fleisher, H. Chen, N. Takebe, and et al. Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib (V) or cixutumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-SCLC) (ECOG 1508) J Clin Oncol 2013 31
13. B.E. Johnson, T. Fischer, B. Fischer, D. Dunlop, D. Rischin, S. Silberman, and et al. Phase II study of imatinib in patients with small cell lung cancer Clin Cancer Res 9 16 Pt 1 2003 5880 5887
14. C.J. Langer, I. Albert, H.J. Ross, P. Kovacs, L.J. Blakely, G. Pajkos, and et al. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer Lung Cancer 85 3 2014 420 428
15. T.K. Owonikoko, G. Zhang, X. Deng, M.R. Rossi, J.M. Switchenko, G.H. Doho, and et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer Cancer Med 2014
16. K.J. Pandya, S. Dahlberg, M. Hidalgo, R.B. Cohen, M.W. Lee, J.H. Schiller, and et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500) J Thorac Oncol 2 11 2007 1036 1041
17. D. Patton, R. Spigel, F.A. Greco, W.H. Liggett, J.D. Zubkus, M. Baskette, and et al. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): update of a phase II trial of the Minnie Pearl Cancer Research Network J Clin Oncol 24 18S 2006 7085
18. N.E. Ready, A.Z. Dudek, H.H. Pang, L.D. Hodgson, S.L. Graziano, M.R. Green, and et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study J Clin Oncol 29 33 2011 4436 4441
19. N.E. Ready, H.H. Pang, L. Gu, G.A. Otterson, S.P. Thomas, A.A. Miller, and et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II Study J Clin Oncol 33 15 2015 May 20 1660 1665
20. C.M. Rudin, R. Salgia, X. Wang, L.D. Hodgson, G.A. Masters, M. Green, and et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103 J Clin Oncol 26 6 2008 870 876
21. B.J. Schneider, G.P. Kalemkerian, N. Ramnath, M.J. Kraut, A.J. Wozniak, F.P. Worden, and et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer Clin Lung Cancer 11 4 2010 223 227
22. N. Sharma, N. Pennell, M. Nickolich, B. Halmos, P. Ma, T. Mekhail, and et al. Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer Invest New Drugs 32 2 2014 362 368
23. D.R. Spigel, F.A. Greco, M.S. Rubin, D. Shipley, D.S. Thompson, E.T. Lubiner, and et al. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer Lung Cancer 77 2 2012 359 364
24. D.R. Spigel, F.A. Greco, J.D. Zubkus, P.B. Murphy, R.A. Saez, C. Farley, and et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer J Thorac Oncol 4 12 2009 1555 1560
25. D.R. Spigel, J.D. Hainsworth, C. Farley, C. Meng, D. Blake, H.A. Burris, and et al. Tracheoesophageal (TE) fistula development in a phase II trial of concurrent chemoradiation (CRT) and bevacizumab (B) in limited-stage small-cell lung cancer (LS-SCLC) J Clin Oncol 26 15S 2008 7554
26. D.R. Spigel, J.D. Hainsworth, L. Simons, C. Meng, H.A. Burris 3rd, D.A. Yardley, and et al. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network J Thorac Oncol 2 9 2007 854 861
27. D.R. Spigel, P.M. Townley, D.M. Waterhouse, L. Fang, I. Adiguzel, J.E. Huang, and et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial J Clin Oncol 29 16 2011 2215 2222
28. J.W. Allen, J. Moon, M. Redman, S.M. Gadgeel, K. Kelly, P.C. Mack, and et al. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer J Clin Oncol 32 23 2014 2463 2470
29. F. de Marinis, A. Atmaca, M. Tiseo, L. Giuffreda, A. Rossi, V. Gebbia, and et al. A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer J Thorac Oncol 8 8 2013 1091 1094
30. L. Gandhi, R. Heist, J. Lucca, J. Temel, P. Fidias, L. Morse, and et al. A phase II trial of pazopanib in relapsed/refractory small cell lung cancer (SCLC) J Clin Oncol 30 2012
31. B.J. Gitlitz, J. Moon, B.S. Glisson, H.J. Reimers, M.J. Bury, J.D. Floyd, and et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial J Thorac Oncol 5 11 2010 1835 1840
32. J.Y. Han, H.Y. Kim, K.Y. Lim, J.H. Han, Y.J. Lee, M.H. Kwak, and et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer Lung Cancer 79 2 2013 137 142
33. R.S. Heist, J. Fain, B. Chinnasami, W. Khan, J.R. Molina, L.V. Sequist, and et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer J Thorac Oncol 5 10 2010 1637 1643
34. S. Jalal, P. Bedano, L. Einhorn, S. Bhatia, R. Ansari, N. Bechar, and et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group J Thorac Oncol 5 12 2010 2008 2011
35. L.M. Krug, J.P. Crapanzano, C.G. Azzoli, V.A. Miller, N. Rizvi, J. Gomez, and et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial Cancer 103 10 2005 2128 2131
36. P.N. Lara Jr., K. Chansky, A.M. Davies, W.A. Franklin, P.H. Gumerlock, P.P. Guaglianone, and et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327) J Thorac Oncol 1 9 2006 996 1001
37. A.M. Moore, L.H. Einhorn, D. Estes, R. Govindan, J. Axelson, J. Vinson, and et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial Lung Cancer 52 1 2006 93 97
38. G. Mountzios, C. Emmanouilidis, N. Vardakis, E. Kontopodis, D. Hatzidaki, E. Popis, and et al. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group Lung Cancer 77 1 2012 146 150
39. C.M. Rudin, C.L. Hann, E.B. Garon, M. Ribeiro de Oliveira, P.D. Bonomi, D.R. Camidge, and et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer Clin Cancer Res 18 11 2012 3163 3169
40. A. Tarhini, A. Kotsakis, W. Gooding, Y. Shuai, D. Petro, D. Friedland, and et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer Clin Cancer Res 16 23 2010 5900 5907
41. Z. Wainberg, S. Rafii, R. Ramanathan, L. Mina, B. LA, R. Chugh, and et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients J Clin Oncol 32 2014 5S
42. D.M. Waterhouse, S.K. Morgan, D.R. Spigel, S. Shankar, B. Dharan, D.E. Foose, and et al. Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer (SCLC) J Clin Oncol 28 15 2010
43. J.L. Pujol, A. Lavole, E. Quoix, O. Molinier, P.J. Souquet, F. Barlesi, and et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trialdagger Ann Oncol 26 5 2015 908 914
44. J.P. Sculier, T. Berghmans, C. Castaigne, S. Luce, C. Sotiriou, P. Vermylen, and et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature Lung Cancer 19 2 1998 141 151
45. A.Z. Abidin, M.C. Garassino, R. Califano, A. Harle, and F. Blackhall Targeted therapies in small cell lung cancer: a review Ther Adv Med Oncol 2 1 2010 25 37
46. P. Salven, T. Ruotsalainen, K. Mattson, and H. Joensuu High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer Int J Cancer 79 2 1998 144 146
47. G. Fontanini, P. Faviana, M. Lucchi, L. Boldrini, A. Mussi, T. Camacci, and et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma Br J Cancer 86 4 2002 558 563
48. F.H. Blackhall, and F.A. Shepherd Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer Hematol Oncol Clin North Am 18 5 2004 1121 1141 ix
49. F. Abdelraouf, E. Smit, B. Hasan, J. Menis, D. Popat, J.P. van Meerbeeck, and et al. Sunitinib (SU11248) in patients with chemo-naïve extensive small cell lung cancer or who have a "chemosensitive" relapse: a Single Arm Phase II study (EORTC-08061) Eur J Cancer 54 2016 35 39
50. A. Badzio, M.W. Wynes, R. Dziadziuszko, D.T. Merrick, M. Pardo, W. Rzyman, and et al. Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer J Thorac Oncol 5 12 2010 1905 1911
51. A. Potti, N. Moazzam, K. Ramar, D.S. Hanekom, S. Kargas, and M. Koch CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma Ann Oncol 14 6 2003 894 897
52. K.S. Park, L.G. Martelotto, M. Peifer, M.L. Sos, A.N. Karnezis, M.R. Mahjoub, and et al. A crucial requirement for Hedgehog signaling in small cell lung cancer Nat Med 17 11 2011 1504 1508
53. M.H. Lawson, N.M. Cummings, D.M. Rassl, S.L. Vowler, M. Wickens, W.J. Howat, and et al. Bcl-2 and beta1-integrin predict survival in a tissue microarray of small cell lung cancer Br J Cancer 103 11 2010 1710 1715
54. M.M. Mortenson, M.G. Schlieman, S. Virudachalam, P.N. Lara, D.G. Gandara, A.M. Davies, and et al. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer Lung Cancer 49 2 2005 163 170
55. M.C. Crisanti, A.F. Wallace, V. Kapoor, F. Vandermeers, M.L. Dowling, L.P. Pereira, and et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer Mol Cancer Ther 8 8 2009 2221 2231
56. L.A. Byers, J. Wang, M.B. Nilsson, J. Fujimoto, P. Saintigny, J. Yordy, and et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1 Cancer Discov 2 9 2012 798 811
57. M. Rouleau, A. Patel, M.J. Hendzel, S.H. Kaufmann, and G.G. Poirier PARP inhibition: PARP1 and beyond Nat Rev Cancer 10 4 2010 293 301
58. L. Virag, and C. Szabo The therapeutic potential of poly(ADP-ribose) polymerase inhibitors Pharmacol Rev 54 3 2002 375 429
59. P.A. Nguewa, M.A. Fuertes, B. Valladares, C. Alonso, and J.M. Perez Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications Prog Biophys Mol Biol 88 1 2005 143 172
60. T.F. Owonikoko, S.E. Dahlberg, S.A. Khan, D.E. Gerber, J. Dowell, R.A. Moss, and et al. A phase 1 study of veliparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (SCLC) patients: an Eastern Cooperative Oncology Group study (E2511) J Clin Oncol 32 5s 2014
61. N. Karachaliou, C. Papadaki, E. Lagoudaki, M. Trypaki, M. Sfakianaki, A. Koutsopoulos, and et al. Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPOmicron-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide PLoS One 8 9 2013 e74611
62. M. Sereno, P. Cejas, V. Moreno, C. Belda-Iniesta, R. Lopez, M. Nistal, and et al. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications Int J Oncol 40 6 2012 2104 2110
63. R.J. Cardnell, Y. Feng, L. Diao, Y.H. Fan, F. Masrorpour, J. Wang, and et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer Clin Cancer Res 19 22 2013 6322 6328
64. N. Turner, A. Tutt, and A. Ashworth Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 10 2004 814 819
65. J. Naidoo, D.B. Page, and J.D. Wolchok Immune modulation for cancer therapy Br J Cancer 111 12 2014 2214 2219
66. A.A. Mostafa, and D.G. Morris Immunotherapy for lung cancer: has it finally arrived? Front Oncol 4 2014 288
67. S.H. Yoon Immunotherapy for non-small cell lung cancer Tuberc Respir Dis (Seoul) 77 3 2014 111 115
68. C.G. Drake, E. Jaffee, and D.M. Pardoll Mechanisms of immune evasion by tumors Adv Immunol 90 2006 51 81
69. T. Pentcheva-Hoang, E. Corse, and J.P. Allison Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections Immunol Rev 229 1 2009 67 87
70. M. Reck, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, R. Chacko, and et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Ann Oncol 24 1 2013 75 83
71. P.A. Ott, M.E.E. Fernandez, S. Hiret, D.W. Kim, A.R. Moss, T. Winser, and et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028 J Clin Oncol 2015 33
72. P.A. Ott, F.S. Hodi, and C. Robert CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients Clin Cancer Res 19 19 2013 5300 5309
73. M.H. Taylor, S.J. Antonia, J.C. Bendell, E. Calvo, D. Jaeger, F.G. De Braud, and et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 J Immunother Cancer 3 S2 2015 376
74. A. Snyder, V. Makarov, T. Merghoub, J. Yuan, J.M. Zaretsky, A. Desrichard, and et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma N Engl J Med 371 23 2014 2189 2199
75. N.A. Rizvi, M.D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J.J. Havel, and et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science 348 6230 2015 124 128
76. S. Panowksi, S. Bhakta, H. Raab, P. Polakis, and J.R. Junutula Site-specific antibody drug conjugates for cancer therapy MAbs 6 1 2014 34 45
77. K. Kontogianni, A.G. Nicholson, D. Butcher, and M.N. Sheppard CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artefact J Clin Pathol 58 9 2005 978 980
78. K.R. Whiteman, H.A. Johnson, M.F. Mayo, C.A. Audette, C.N. Carrigan, A. LaBelle, and et al. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models MAbs 6 2 2014 556 566
79. D.C. Roy, S. Ouellet, C. Le Houillier, P.D. Ariniello, C. Perreault, and J.M. Lambert Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin J Natl Cancer Inst 88 16 1996 1136 1145
80. A. Beck, J. Lambert, M. Sun, and K. Lin Fourth world antibody-drug conjugate summit MAbs 4 6 2012 637 647
81. L.R. Saunders, A.J. Bankovich, W.C. Anderson, M.A. Aujay, S. Bheddah, K. Black, and et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo Sci Transl Med 7 302 2015 302ra136
82. C.M. Rudin, M. Pietanza, D.R. Spigel, T.M. Bauer, B. Glisson, F. Robert, and et al. A DLL3-targeted ADC, rovalpituzumab tesirine, demonstrates substantial activity in a phase I study in relapsed and refractory SCLC 16th World Conference on Lung Cancer 2015 Denver, Colorado, USA
83. C.L. Hodgkinson, C.J. Morrow, Y. Li, R.L. Metcalf, D.G. Rothwell, F. Trapani, and et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer Nat Med 20 8 2014 897 903